Fig. 2: Prior priming by infection accentuates mRNA vaccine antibody profile to sarbecovirus RBD.
From: Priming conditions shape breadth of neutralizing antibody responses to sarbecoviruses
The % antibody inhibition of ACE2 binding to RBD was determined for a uninfected subjects pre and 1 month post 2 dose vaccination with BNTb162b2 (B) or Coronavac (C) (n = 30 subjects). b COVID-19 infected 1 month post 1 dose vaccination with BNT162b2 (SARS2 + B) or Coronavac (SARS2 + C) (n = 20 subjects, prior infection 346+/−105 days before vaccination). c Hong Kong (HK) SARS-CoV-1 infected patients (SARS1) 1 month post 2 dose vaccination with BNT162b2 (SARS1 + B, n = 7 subjects) or Coronavac (SARS1 + C, n = 2 subjects). d Guangzhou (GZ) SARS-CoV-1 infected patients from 2018 (n = 10 subjects) and post 2 dose vaccination with Sinopharm (SARS1 + S) at 1 to 6 months post vaccination (1 M n = 6 subjects, 3 M n = 5 subjects, 6 M n = 2 subjects). e Heat map representation of % inhibition of 1 month post vaccination (from a–d). a–d Data represented mean+/− stdev and individual samples. a, c Significant differences in paired pre versus post vaccine responses within vaccine type by one-way Friedmans tests with Dunns multiple comparisons (coloured, within vaccine type). b, d one-way Kruskall Wallis test with Dunns multiple comparisons between vaccine types (a, b) or versus 2018 (d) (black, statistical differences). *p  < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ^ for BNT pre versus post and # for Coronavac pre versus post.
